For research use only. Not for therapeutic Use.
NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC50 value of 7 nM. NLRP3-IN-17 significantly inhibits NLRP3 dependent IL-1β secretion in mice and can be used for chronic inflammatory diseases research[1].
NLRP3-IN-17 (compound 15) (3 mg/kg; po) displays desired PK profile, the AUC, t and F% values are 4.2 μg.h/mL, 2.91 h, and 56%, respectively[1].
NLRP3-IN-17 (10 mg/kg; po; single dosage) significantly inhibit NLRP3 dependent IL-1β secretion in acute in vivo LPS+ATP
challenged model in female C57BL/6 mice, it decreases the IL-1β levels by 44%[1].
| Catalog Number | I041169 |
| CAS Number | 2254432-75-0 |
| Synonyms | 1-[N-cyano-S-(4-methylphenyl)sulfonimidoyl]-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea |
| Molecular Formula | C21H22N4O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H22N4O2S/c1-14-8-10-17(11-9-14)28(27,23-13-22)25-21(26)24-20-18-6-2-4-15(18)12-16-5-3-7-19(16)20/h8-12H,2-7H2,1H3,(H2,23,24,25,26,27) |
| InChIKey | SOZVZFKPLUXVMT-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)S(=NC#N)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4 |
| Reference | [1]. Sameer Agarwal, et al. Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors. ACS Med Chem Lett. 2020 Feb 27;11(4):414-418. |
